Transgenic Group (2342) · InitiativeAdvanced
Use of PDSX in Nonclinical Testing Through a Business Alliance with 京ダイアグノスティクス
First written in FY2019-Q3. 1 of 2 entries say "Advanced", first in FY2019. Latest entry: FY2019.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Partnership with 京ダイアグノスティクス for nonclinical testing using PDSX model miceA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2019AdvancedAnnual report
「The company is also working on the development and introduction of versatile antibody products, and has begun developing an anticancer drug for colorectal cancer in partnership with 京ダイアグノスティクス株式会社.」
The scope of the collaboration with 京ダイアグノスティクス has expanded from using model mice in nonclinical studies to beginning development of an anticancer drug for colorectal cancer. - FY2019-Q3First statedAnnual report
「The company worked to use model mice in nonclinical studies, including by entering into a business alliance with 京ダイアグノスティクス株式会社, which produces PDSX for use in nonclinical studies.」
The company has described for the first time a new initiative to use model mice in nonclinical studies through its business alliance with 京ダイアグノスティクス株式会社, which produces PDSX.